Role of cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression in the pathogenesis of Warthin's tumor growth
Downloads
Background: One of the benign salivary gland tumors is Warthin's tumor, which is a benign tumor consisting of a papillary cystic structure covered by a double epithelial layer cells and lymphoid stroma with germinal center. Several cases have reported the Warthin's tumor transformation into a malignant tumor such as lymphoma that develops from their stromal. Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) as part of the immune checkpoint when highly expressed leads to a more rapid development or progression of tumors. Purpose: To analyze CTLA-4 expression in Warthin's tumors associated with the pathogenesis of its growth through an escape mechanism from immune checkpoints and analyze based on CTLA expression whether this marker has the potential to be used as immunotherapy by administering anti CTLA-4. Methods: The tissue sections slides of Warthin's tumor (n=8) were stained with Hematoxylin Eosin and immunostained with Recombinant Anti-CTLA4 antibody [CAL49] (ab237712). The slide with positive CTLA-4 is shown as staining on the cell membrane and/or cytoplasm. Observations were carried out using Optilab. The result is presented as figures. Results: Tumor cells expressed of CTLA-4 show in cytoplasm and/or cell membranes of the epithelial and stromal components of Warthin's lymphoid. CTLA-4 is expressed lymphoid stroma, which is associated with inhibition of T cell activity against tumor cells, while the exact mechanism of CTLA-4 expression in epithelial components is not known but is thought to induce tumorigenesis and inhibit apoptosis. Conclusion: CTLA-4 is expressed in epithelial and stromal cells of Warthin's tumor and this expression indicates that Warthin's tumor cell growth is through the escape mechanism of the CTLA-4 check point immune. Further research is necessary to investigate whether CTLA-4 expression in lymphoid stroma has relate to their transformation toward a malignant tumor of lymphoma.
Downloads
Diaz-Segarra N, Young LK, Levin K, Rafferty W, Brody J, Koshkareva Y. Warthin tumor of the oropharyngeal minor salivary gland. SAGE Open Med Case Reports. 2018; 6: 2050313X1881871. doi: https://doi.org/10.1177/2050313X18818712
Neville B, Damm D, Allen C, Chi A. Oral and maxillofacial pathology. 4th ed. Missouri: WB Saunders, Elsevier; 2016. p. 449–450. web: https://evolve.elsevier.com/cs/product/9781455770526?CT=ID
Kuzenko Y V, Romanuk AM, Dyachenko OO, Hudymenko O. Pathogenesis of Warthin's tumors. Interv Med Appl Sci. 2016; 8(2): 41–8. doi: https://doi.org/10.1556/1646.8.2016.2.2
Ozkök G, Taşlı F, Ozsan N, Oztürk R, Postacı H. Diffuse large B-cell lymphoma arising in Warthin's tumor: case study and review of the literature. Korean J Pathol. 2013; 47(6): 579–82. doi: https://doi.org/10.4132/KoreanJPathol.2013.47.6.579
Kumar V, Abbas A, Aster J. Robbins basic pathology. 10th ed. Elsevier; 2017. p. 225. web: https://www.elsevier.com/books/robbins-basic-pathology/kumar/978-0-323-35317-5
Peng Z, Su P, Yang Y, Yao X, Zhang Y, Jin F, Yang B. Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis. J Cancer. 2020; 11(21): 6365–75. doi: https://doi.org/10.7150/jca.46301
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18(1): 10. doi: https://doi.org/10.1186/s12943-018-0928-4
Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 2018; 47(2): 721–34. doi: https://doi.org/10.1159/000490025
Lawrenti H. Perkembangan imunoterapi untuk kanker. Cermin Dunia Kedokt. 2018; 45(8): 616–22. web: http://www.cdkjournal.com/index.php/CDK/article/download/634/405
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018; 8: 86. doi: https://doi.org/10.3389/fonc.2018.00086
Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39(1): 98–106. doi: https://doi.org/10.1097/COC.0000000000000239
Szostak B, Machaj F, Rosik J, Pawlik A. CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. Expert Opin Investig Drugs. 2019; 28(2): 149–59. doi: https://doi.org/10.1080/13543784.2019.1559297
Syafriadi M, Ummah DZ, Muna AI, Surya MEK. Progressivity analysis of pleomorphic adenoma toward carcinoma ex pleomorphic adenoma. Dent J (Majalah Kedokt Gigi). 2022; 55(1): 1–6. doi: https://doi.org/10.20473/j.djmkg.v55.i1.p1-6
Tiemann M, Atiakshin D, Samoilova V, Buchwalow I. Identification of CTLA-4-positive cells in the human tonsil. Cells. 2021; 10(5). doi: https://doi.org/10.3390/cells10051027
Oyewole-Said D, Konduri V, Vazquez-Perez J, Weldon SA, Levitt JM, Decker WK. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types. Front Immunol. 2020; 11: 608024. doi: https://doi.org/10.3389/fimmu.2020.608024
Paulsen E-E, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund L-T, Bremnes RM, Donnem T. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother. 2017; 66(11): 1449–61. doi: https://doi.org/10.1007/s00262-017-2039-2
Navarrete-Bernal MGC, Cervantes-Badillo MG, Martínez-Herrera JF, Lara-Torres CO, Gerson-Cwilich R, Zentella-Dehesa A, Ibarra-Sánchez M de J, Esparza-López J, Montesinos JJ, Cortés-Morales VA, Osorio-Pérez D, Villegas-Osorno DA, Reyes-Sánchez E, Salazar-Sojo P, Tallabs-Utrilla LF, Romero-Córdoba S, Rocha-Zavaleta L. Biological landscape of triple negative breast cancers expressing CTLA-4. Front Oncol. 2020; 10: 1206. doi: https://doi.org/10.3389/fonc.2020.01206
Zhang B, Dang J, Ba D, Wang C, Han J, Zheng F. Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells. Oncol Lett. 2018; 16(5): 6163–70. doi: https://doi.org/10.3892/ol.2018.9354
Nguyen KA, Thai TA, Giang CT. Malignant transformation in a parotid Warthin's tumor: clinical features and histopathological examination. J Cancer Biol Res. 2018; 6(1): 1115. pdf: https://www.jscimedcentral.com/CancerBiology/cancerbiology-6-1114.pdf
Zhang H, Dutta P, Liu J, Sabri N, Song Y, Li WX, Li J. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer. J Cell Mol Med. 2019; 23(1): 535–42. doi: https://doi.org/10.1111/jcmm.13956
Brown C, Sekhavati F, Cardenes R, Windmueller C, Dacosta K, Rodriguez-Canales J, Steele KE. CTLA-4 immunohistochemistry and quantitative image analysis for profiling of human cancers. J Histochem Cytochem. 2019; 67(12): 901–18. doi: https://doi.org/10.1369/0022155419882292
Nurhayati B, Darmawati S. Biologi sel & molekuler. Jakarta: Pusat Pendidikan Sumber Daya Manusia Kesehatan, Kementerian Kesehatan Republik Indonesia; 2017. p. 71. pdf: http://bppsdmk.kemkes.go.id/pusdiksdmk/wp-content/uploads/2017/11/BIOLOGI-SEL-DAN-MOLEKULER-SC.pdf
Chen M, Long Q, Borrie MS, Sun H, Zhang C, Yang H, Shi D, Gartenberg MR, Deng W. Nucleoporin TPR promotes tRNA nuclear export and protein synthesis in lung cancer cells. PLoS Genet. 2021; 17(11): e1009899. doi: https://doi.org/10.1371/journal.pgen.1009899
Copyright (c) 2022 Dental Journal (Majalah Kedokteran Gigi)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Every manuscript submitted to must observe the policy and terms set by the Dental Journal (Majalah Kedokteran Gigi).
- Publication rights to manuscript content published by the Dental Journal (Majalah Kedokteran Gigi) is owned by the journal with the consent and approval of the author(s) concerned.
- Full texts of electronically published manuscripts can be accessed free of charge and used according to the license shown below.
- The Dental Journal (Majalah Kedokteran Gigi) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
